ATE186841T1 - Methode zum erzeugen von analgie mittels neurotrophine - Google Patents

Methode zum erzeugen von analgie mittels neurotrophine

Info

Publication number
ATE186841T1
ATE186841T1 AT93921561T AT93921561T ATE186841T1 AT E186841 T1 ATE186841 T1 AT E186841T1 AT 93921561 T AT93921561 T AT 93921561T AT 93921561 T AT93921561 T AT 93921561T AT E186841 T1 ATE186841 T1 AT E186841T1
Authority
AT
Austria
Prior art keywords
neurotrophins
aalgia
producing
neurotrophin
infusions
Prior art date
Application number
AT93921561T
Other languages
English (en)
Inventor
Judith Siuciak
Charles A Altar
Ronald M Lindsay
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE186841T1 publication Critical patent/ATE186841T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
AT93921561T 1992-09-14 1993-09-14 Methode zum erzeugen von analgie mittels neurotrophine ATE186841T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94482392A 1992-09-14 1992-09-14
US11039993A 1993-08-23 1993-08-23

Publications (1)

Publication Number Publication Date
ATE186841T1 true ATE186841T1 (de) 1999-12-15

Family

ID=26807990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93921561T ATE186841T1 (de) 1992-09-14 1993-09-14 Methode zum erzeugen von analgie mittels neurotrophine

Country Status (8)

Country Link
US (1) US5827823A (de)
EP (1) EP0666756B1 (de)
JP (1) JPH08501313A (de)
AT (1) ATE186841T1 (de)
AU (1) AU4920893A (de)
CA (1) CA2144539A1 (de)
DE (1) DE69327113D1 (de)
WO (1) WO1994006455A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109280A0 (en) * 1993-04-15 1994-07-31 Regeneron Pharma Neurotrophins for treatment of depression
GB9608335D0 (en) * 1996-04-23 1996-06-26 Univ Kingston Method of enhancing ngf-mediated neurite growth with low molecular weight analoues of p.75 ngfr 367-379
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US20040120891A1 (en) * 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
WO2000067032A1 (en) * 1999-05-03 2000-11-09 Evotec Biosystems Ag Methods of diagnosing or treating depression
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
WO2004029624A1 (ja) * 2002-09-24 2004-04-08 Masaomi Iyo 摂食障害の診断薬および検定方法
BRPI0506793A (pt) * 2004-02-20 2007-05-22 Rinat Neuroscience Corp métodos de tratamento de obesidade ou diabetes com o uso de nt-4/5
US7935342B2 (en) * 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
US20070248611A1 (en) * 2006-02-02 2007-10-25 Pfizer Inc Methods wanted for treating unwanted weight loss or eating disorders by administering a trkb agonist
EP3823674A4 (de) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. Konjugate zur abgabe eines krebsmittels an nervenzellen, verwendungsverfahren und verfahren zu deren herstellung

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753635A (en) * 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
JP3187410B2 (ja) * 1989-08-10 2001-07-11 住友製薬株式会社 脳内投与用徐放性製剤

Also Published As

Publication number Publication date
EP0666756A1 (de) 1995-08-16
WO1994006455A1 (en) 1994-03-31
EP0666756B1 (de) 1999-11-24
AU4920893A (en) 1994-04-12
DE69327113D1 (de) 1999-12-30
US5827823A (en) 1998-10-27
JPH08501313A (ja) 1996-02-13
CA2144539A1 (en) 1994-03-31

Similar Documents

Publication Publication Date Title
ATE186841T1 (de) Methode zum erzeugen von analgie mittels neurotrophine
DE69424545D1 (de) Verfahren zur herstellung von immunoglobulin g konzentrat
DK0412149T3 (da) Anvendelse af IL-7 til tilvejebringelse af lægemidler til stimulering af blodpladeproduktion
DE69634301D1 (de) Methode zur behandlung von alzheimer mit einem von einer gliazelllinie stammenden neurotrophen protein (gdnf)
DE69328474D1 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
DK0866719T3 (da) Fremgangsmåde til behandling af retina-gangliecellelæsion under anvendelse af gliacellelinjeafladt neurotrof faktor (GDNF)-
ATE227124T1 (de) Behandlung von multipler sklerose (ms) und anderen demyelinisationserkrankungen unter verwendung von lofepramin in kombination mit l- phenylalamin, tyrosin oder tryptophan und evtl. einer vitamin b12-verbindung
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
DE69520430D1 (de) Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
ATE246248T1 (de) Anti-hiv-proteine gap31, dap30 und dap32, die sie kodierende dna und ihre therapeutische nutzung
DE3784988D1 (de) Methode fuer selektiven zuwachs des anteils der gewoenlichen hauptkomponente des antibiotischen komplexes a/16686.
ATE169641T1 (de) Verfahren zur herstellung von stärkeabbauprodukten
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
ES2052531T3 (es) Metodo para aumentar selectivamente la relacion de los componentes individuales del complejo antibiotico a 40926.
ATE228006T1 (de) Verwendung von vip zur erstellung eines medikamentes zur behandlung des endotoxischen schocks in säugetieren
DK0593516T3 (da) Fremgangsmåder til behandling af motorneuronsygdomme ved anvendelse af medlemmer af BDNF/NT-3/NGF-molekylfamilien
ATE245991T1 (de) Behandlung chronischer entzündungskrankheiten mit cm101/gbs-toxin
ATE121388T1 (de) 3- oder 4-substituierte oxotremorin-derivate.
ES2138734T3 (es) Procedimiento para la preparacion de derivados de 1-(3-trialquilsililfenil)-2,2,2-trifluormetil etanona.
DE68924545D1 (de) Verwendung von Chinolizin- und Chinolizinon-Derivaten zur Herstellung von Arzneimitteln.
MY130951A (en) Process for producing lactoprotein-containing acidified beverage
Eagleson et al. A study of chord preference in a group of Negro college women.
DE69415990D1 (de) Heterodimere der wachstumsfaktoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties